Guest guest Posted December 21, 2010 Report Posted December 21, 2010 http://www.pharmalot.com/2010/12/house-democrats-introduce-drug-safety-legislati\ on/ Thoughts? Terry  • â Pharma Blogâ » â 2010â » â Decemberâ » â 21â â House Democrats Introduce Drug Safety Legislationâ Make a comment By Ed Silverman // â December 21st, 2010â // 9:38 am As promised, a handful of House Democrats have introduced legislation that would increase funding and authority for the FDA to monitor drug production - both domestically and overseas - in hopes of improving safety in the wake of the Heparin scandal and other recent episodes that questioned foreign production of meds sold in the US. The bill would crreate an up-to-date registry of all domestic and foreign facilities serving the US; generate funding for increased Good Manufacturing Practices (GMP) inspections for brand and generic drugs; require parity between foreign and domestic inspections; prohibit entry of drugs coming from domestic and foreign facilities that limit, delay or deny FDA inspections; prohibit drugs from entering the US if safety documentation is lacking; requires manufacturers to document measures taken to secure supply chains; and prohibit false or misleading reports to the FDA. Known as HR 6543, the Drug Safety Enhancement Act, would also give the FDA additional enforcement tools - such as mandatory recall authority, increased civil and criminal penalties, and new authority to subpoena records related to possible violations. There would also be provides protection for whistleblowers who disclose safety information. And unique ID numbers would be given drugmakers, facilities and importers so the FDA can more readily identify entities (â read the bill hereâ ). The bill was introduced Friday by Henry Waxman, who is the outgoing chair of the House Energy and Commerce Committee; along with chairman emeritus Dingell; Rep. Pallone, who chairs the Subcommittee on Health; and Bart Stupak, chair of the Subcommittee on Oversight and Investigations. Whether the bill will ever become law remains unclear, given that Republicans are about to control the House. On the other hand, Joe Barton, the top Republican on the House Energy and Commerce Committee, has repeatedly lambasted the FDA for failing to more thoroughly probe the Heparin scandal (â back storyâ ) and may want to embrace some of these provisions. Sent via BlackBerry by AT & T Quote
Guest guest Posted December 21, 2010 Report Posted December 21, 2010 http://www.pharmalot.com/2010/12/house-democrats-introduce-drug-safety-legislati\ on/ Thoughts? Terry  • â Pharma Blogâ » â 2010â » â Decemberâ » â 21â â House Democrats Introduce Drug Safety Legislationâ Make a comment By Ed Silverman // â December 21st, 2010â // 9:38 am As promised, a handful of House Democrats have introduced legislation that would increase funding and authority for the FDA to monitor drug production - both domestically and overseas - in hopes of improving safety in the wake of the Heparin scandal and other recent episodes that questioned foreign production of meds sold in the US. The bill would crreate an up-to-date registry of all domestic and foreign facilities serving the US; generate funding for increased Good Manufacturing Practices (GMP) inspections for brand and generic drugs; require parity between foreign and domestic inspections; prohibit entry of drugs coming from domestic and foreign facilities that limit, delay or deny FDA inspections; prohibit drugs from entering the US if safety documentation is lacking; requires manufacturers to document measures taken to secure supply chains; and prohibit false or misleading reports to the FDA. Known as HR 6543, the Drug Safety Enhancement Act, would also give the FDA additional enforcement tools - such as mandatory recall authority, increased civil and criminal penalties, and new authority to subpoena records related to possible violations. There would also be provides protection for whistleblowers who disclose safety information. And unique ID numbers would be given drugmakers, facilities and importers so the FDA can more readily identify entities (â read the bill hereâ ). The bill was introduced Friday by Henry Waxman, who is the outgoing chair of the House Energy and Commerce Committee; along with chairman emeritus Dingell; Rep. Pallone, who chairs the Subcommittee on Health; and Bart Stupak, chair of the Subcommittee on Oversight and Investigations. Whether the bill will ever become law remains unclear, given that Republicans are about to control the House. On the other hand, Joe Barton, the top Republican on the House Energy and Commerce Committee, has repeatedly lambasted the FDA for failing to more thoroughly probe the Heparin scandal (â back storyâ ) and may want to embrace some of these provisions. Sent via BlackBerry by AT & T Quote
Guest guest Posted December 21, 2010 Report Posted December 21, 2010 http://www.pharmalot.com/2010/12/house-democrats-introduce-drug-safety-legislati\ on/ Thoughts? Terry  • â Pharma Blogâ » â 2010â » â Decemberâ » â 21â â House Democrats Introduce Drug Safety Legislationâ Make a comment By Ed Silverman // â December 21st, 2010â // 9:38 am As promised, a handful of House Democrats have introduced legislation that would increase funding and authority for the FDA to monitor drug production - both domestically and overseas - in hopes of improving safety in the wake of the Heparin scandal and other recent episodes that questioned foreign production of meds sold in the US. The bill would crreate an up-to-date registry of all domestic and foreign facilities serving the US; generate funding for increased Good Manufacturing Practices (GMP) inspections for brand and generic drugs; require parity between foreign and domestic inspections; prohibit entry of drugs coming from domestic and foreign facilities that limit, delay or deny FDA inspections; prohibit drugs from entering the US if safety documentation is lacking; requires manufacturers to document measures taken to secure supply chains; and prohibit false or misleading reports to the FDA. Known as HR 6543, the Drug Safety Enhancement Act, would also give the FDA additional enforcement tools - such as mandatory recall authority, increased civil and criminal penalties, and new authority to subpoena records related to possible violations. There would also be provides protection for whistleblowers who disclose safety information. And unique ID numbers would be given drugmakers, facilities and importers so the FDA can more readily identify entities (â read the bill hereâ ). The bill was introduced Friday by Henry Waxman, who is the outgoing chair of the House Energy and Commerce Committee; along with chairman emeritus Dingell; Rep. Pallone, who chairs the Subcommittee on Health; and Bart Stupak, chair of the Subcommittee on Oversight and Investigations. Whether the bill will ever become law remains unclear, given that Republicans are about to control the House. On the other hand, Joe Barton, the top Republican on the House Energy and Commerce Committee, has repeatedly lambasted the FDA for failing to more thoroughly probe the Heparin scandal (â back storyâ ) and may want to embrace some of these provisions. Sent via BlackBerry by AT & T Quote
Guest guest Posted December 21, 2010 Report Posted December 21, 2010 http://www.pharmalot.com/2010/12/house-democrats-introduce-drug-safety-legislati\ on/ Thoughts? Terry  • â Pharma Blogâ » â 2010â » â Decemberâ » â 21â â House Democrats Introduce Drug Safety Legislationâ Make a comment By Ed Silverman // â December 21st, 2010â // 9:38 am As promised, a handful of House Democrats have introduced legislation that would increase funding and authority for the FDA to monitor drug production - both domestically and overseas - in hopes of improving safety in the wake of the Heparin scandal and other recent episodes that questioned foreign production of meds sold in the US. The bill would crreate an up-to-date registry of all domestic and foreign facilities serving the US; generate funding for increased Good Manufacturing Practices (GMP) inspections for brand and generic drugs; require parity between foreign and domestic inspections; prohibit entry of drugs coming from domestic and foreign facilities that limit, delay or deny FDA inspections; prohibit drugs from entering the US if safety documentation is lacking; requires manufacturers to document measures taken to secure supply chains; and prohibit false or misleading reports to the FDA. Known as HR 6543, the Drug Safety Enhancement Act, would also give the FDA additional enforcement tools - such as mandatory recall authority, increased civil and criminal penalties, and new authority to subpoena records related to possible violations. There would also be provides protection for whistleblowers who disclose safety information. And unique ID numbers would be given drugmakers, facilities and importers so the FDA can more readily identify entities (â read the bill hereâ ). The bill was introduced Friday by Henry Waxman, who is the outgoing chair of the House Energy and Commerce Committee; along with chairman emeritus Dingell; Rep. Pallone, who chairs the Subcommittee on Health; and Bart Stupak, chair of the Subcommittee on Oversight and Investigations. Whether the bill will ever become law remains unclear, given that Republicans are about to control the House. On the other hand, Joe Barton, the top Republican on the House Energy and Commerce Committee, has repeatedly lambasted the FDA for failing to more thoroughly probe the Heparin scandal (â back storyâ ) and may want to embrace some of these provisions. Sent via BlackBerry by AT & T Quote
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.